Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Legislative and technical aspects of mutagenicity testing.

V W Mayer, W G Flamm

Mutation Research

|August 1, 1975

Summary

The U.S. Food and Drug Administration (FDA) faces challenges in mutagenicity testing despite adequate authority. A new tiered testing system is proposed to improve the safety assessment of foods, drugs, and cosmetics.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Elevating the terms of the GM food debate.

Regulatory toxicology and pharmacology : RTP·2001

Same author

Safety evaluation of dietary aluminum.

Regulatory toxicology and pharmacology : RTP·2001

Same author

Toxicity and mutagenicity studies of DN-50000((R)) and RP-1((R)) enzymes.

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association·2000

Same author

Evaluation of safety of inulin and oligofructose as dietary fiber.

Regulatory toxicology and pharmacology : RTP·2000

Same author

A review of the studies of the safety of polydextrose in food.

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association·1999

Same author

Does the term carcinogen send the wrong message?

Cancer letters·1997

Area of Science:

Toxicology
Genetics
Regulatory Science

Background:

The U.S. Food and Drug Administration (FDA) is legislatively mandated to ensure the safety of foods, drugs, and cosmetics.
Existing FDA authority is sufficient, but technological and scientific limitations hinder effective mutagenicity testing.

Purpose of the Study:

To address the scientific and practical deficiencies in current mutagenicity screening methods.
To propose and evaluate a new tiered testing system for mutagenicity assessment.

Main Methods:

Review of historical legislative acts and FDA responsibilities.
Description of a proposed three-tier mutagenicity testing system: initial screening, confirmation in mammals, and explicit genetic risk assessment.
Overview of ongoing FDA research activities, including in-house, contract, and collaborative efforts.

Main Results:

Previous mutagenicity testing approaches (host-mediated assay, somatic cell cytogenetics, dominant lethal tests) were found to have significant deficiencies.
The proposed tier system offers a structured approach with increasing complexity for more accurate mutagenicity detection and risk assessment.
FDA is actively researching the tier system's effectiveness through various research initiatives.

Conclusions:

The tier system represents a promising advancement for mutagenicity safety screening within the FDA.
Continued research is crucial to validate the tier system and address potential deficiencies in assessing environmental mutagenic risks.

Related Experiment Videos